Document Detail

Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma.
MedLine Citation:
PMID:  12562656     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: To determine the incidence of early cardiotoxicity induced by the CHOP regimen in patients with aggressive non-Hodgkin's lymphoma (NHL) and to identify associated risk factors. PATIENTS AND METHODS: A retrospective analysis included 135 consecutive patients who had been treated with the CHOP (cyclophosphamide, doxorubicin, vincristin, prednisone) regimen as first-line therapy between 1994 and 2000. The cardiac evaluation was based on a determination of the resting left ventricular ejection function (LVEF) by gated blood-pool imaging. Cardiotoxicity was defined as a significant decrease in LVEF or clinical evidence of congestive heart failure (CHF). RESULTS: Twenty-seven (20%) patients developed a cardiac event within 1 year of treatment. Among these, 14 patients had clinical signs of CHF. Three patients died suddenly from presumed cardiac causes. In multivariate analysis, a cumulative dose of doxorubicin >200 mg/m(2) [odds ratio (OR) = 4.2, P = 0.005)] and age over 50 years (OR = 2.9, P = 0.03) appeared to be significant risk factors. CONCLUSION: Early clinical and subclinical cardiotoxicity was frequent in patients receiving the CHOP regimen. The threshold of the cumulative dose of doxorubicin appeared to be low: at doses >200 mg/m(2), 27% of patients had cardiac events. Elderly patients appeared to be at higher risk. The development of cardioprotective strategies or alternative treatments are mandatory for aggressive NHL patients.
S Limat; K Demesmay; L Voillat; Y Bernard; E Deconinck; A Brion; A Sabbah; M C Woronoff-Lemsi; J Y Cahn
Related Documents :
3800726 - Can embolic stroke be diagnosed on the basis of neurologic clinical criteria?
6613526 - Cardiac conduction disturbances during carbamazepine therapy.
12887336 - Ultrastructure of the gingiva in cardiac patients treated with or without calcium chann...
11928786 - Bupropion (zyban) toxicity.
3410586 - Ibopamine kinetics after a single oral dose in patients with congestive heart failure.
21061256 - Body mass index and clinical response to infliximab in rheumatoid arthritis.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  14     ISSN:  0923-7534     ISO Abbreviation:  Ann. Oncol.     Publication Date:  2003 Feb 
Date Detail:
Created Date:  2003-02-03     Completed Date:  2003-06-04     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  277-81     Citation Subset:  IM    
Department of Pharmacy, Besançon University Hospital, Besançon, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Antineoplastic Combined Chemotherapy Protocols / administration & dosage,  adverse effects*,  therapeutic use*
Cyclophosphamide / administration & dosage,  adverse effects
Dose-Response Relationship, Drug
Doxorubicin / administration & dosage,  adverse effects
Heart Failure / chemically induced*
Lymphoma, Non-Hodgkin / drug therapy*,  pathology
Middle Aged
Prednisone / administration & dosage,  adverse effects
Retrospective Studies
Risk Factors
Ventricular Dysfunction, Left / chemically induced*
Vincristine / administration & dosage,  adverse effects
Reg. No./Substance:
0/CHOP protocol; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 57-22-7/Vincristine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large ...
Next Document:  The effect of Epstein-Barr virus status on outcome in age- and sex-defined subgroups of patients wit...